TECENTRIQ by Roche is l1 may be expressed on tumor cells and/or tumor infiltrating immune cells and can contribute to the inhibition of the anti-tumor immune response in the tumor microenvironment. Approved for following platinum-containing chemotherapy, metastatic hepatocellular carcinoma (hcc). First approved in 2016.
Drug data last refreshed 16h ago · AI intelligence enriched 2mo ago
TECENTRIQ (atezolizumab) is a monoclonal antibody that blocks the Programmed Death Receptor-1 (PD-1) pathway, enabling the immune system to recognize and attack cancer cells. It is administered intravenously and is approved across multiple solid tumor indications including non-small cell lung cancer, triple-negative breast cancer, and urothelial carcinoma. The drug represents a cornerstone immunotherapy in Roche's oncology portfolio.
Peak lifecycle status indicates mature portfolio with established teams; commercial focus is on market share defense and combination indication expansion rather than aggressive growth.
L1 may be expressed on tumor cells and/or tumor infiltrating immune cells and can contribute to the inhibition of the anti-tumor immune response in the tumor microenvironment. Binding of PD L1 to the PD 1 and B7.1 receptors found on T cells and antigen presenting cells suppresses cytotoxic T-cell…
Worked on TECENTRIQ at Roche? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista
A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma
A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)
A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moRoles on TECENTRIQ offer exposure to a flagship oncology asset in peak commercial phase, with focus on competitive defense and indication expansion. Career growth is tied to market share retention and successful launch of combination formulations like TECENTRIQ HYBREZA rather than greenfield market creation.